Timothy G. G. Murray

Dr. Timothy G. G. Murray

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Ophthalmology Retina
Verified
Journal Article
Closed access
TMTimothy G. G. Murray
Timothy G. G. Murray
ALAzeema Latiff
Azeema Latiff
VVVictor M. Villegas
Victor M. Villegas
AGAaron S. Gold
Aaron S. Gold

28 February 2013 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
TMTimothy G. G. Murray
Timothy G. G. Murray
AMArnold M. Markoe
Arnold M. Markoe
AGAaron S. Gold
Aaron S. Gold
FEFiona Ehlies
Fiona Ehlies
EBErnesto Bermudez
Ernesto Bermudez
ALAzeema Latiff
Azeema Latiff
Objective. To investigate the efficacy of two different dosing strategies of radioactive iodine-125 (125I) in the management of small- and medium-sized posterior uveal melanoma. Patients and Methods. The medical records of consecutive patients with choroidal melanomas between 1.5 and 5.0mm in apical height treated initially with 125I plaque radiotherapy were reviewed. Patients were treated with one of the following two treatment dosing strategies: (1) 85Gy to the apical height of the tumor (group 1) or (2) 85Gy to a prescription point of 5.0mm (group 2). Results. Of 95 patients, 55 patients were treated to the apical height of the tumor, and 40 were treated to a prescription point of 5.0 mm. Comparative analysis of the incidence rates of specific complications between the two groups demonstrates that group 2 had a significantly higher incidence of radiation retinopathy, radiation optic neuropathy, and/or visually significant cataract formation than group 1 (). Conclusion. Treatment of choroidal melanomas less than 5mm in apical height with 125I brachytherapy to the true apical height is equally effective when compared to treatment with 85Gy to 5.0mm. Treatment to the apical height of the tumor may result in lower incidence of radiation-related complications.

1 October 2012 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
TMTimothy G. G. Murray
Timothy G. G. Murray
NSNisha V Shah
Nisha V Shah
SHSamuel Samuel Houston
Samuel Samuel Houston
WFWilliam Feuer
William Feuer
AMArnold M Markoe
Arnold M Markoe
Purpose: To evaluate the benefits of intravitreal bevacizumab in patients with visually compromising radiation maculopathy following iodine-125 plaque brachytherapy for uveal melanoma. Methods: In this Institutional Review Board-approved, consecutive, retrospective study from 2006–2009 of patients maintaining 20/50 or better vision following treatment for visually compromising radiation maculopathy, patients were evaluated with spectral domain optical coherence tomography at 2–4 month intervals following plaque removal. Treatment with intravitreal bevacizumab commenced at the first signs of radiation vasculopathy on spectral domain optical coherence tomography with associated decreased best corrected visual acuity, followed by repeat injections for recurrent or persistent vasculopathic changes. Results: At 3 years following plaque brachytherapy, 81 of 159 (50.9%) patients treated for radiation maculopathy demonstrated 20/50 or better vision at median follow up of 36 months, which demonstrates significant improvement in vision as compared to the Collaborative Ocular Melanoma Study (P < 0.0001). These 81 patients were given a mean of five injections (range 1–17) over a mean of 17.6 months (range 1–54 months), starting at 15.8 months (range 3–50 months) after plaque brachytherapy. For those eyes that maintained 20/50 or better vision at the final follow-up, pretreatment mean best corrected visual acuity of 20/43 improved to 20/31. Conclusion: This study demonstrates that spectral domain optical coherence tomography can detect early vasculopathic changes secondary to radiation maculopathy and that prompt treatment with intravitreal bevacizumab may delay vision loss and maintain or possibly improve visual acuity in half of eyes diagnosed with radiation maculopathy. Radiation maculopathy remains a therapeutically manageable morbidity associated with radiation therapy for posterior uveal melanoma.

1 July 2003 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
MMMichele Melia
Michele Melia
CMClaudia S Moy
Claudia S Moy
SRSandra M Reynolds
Sandra M Reynolds
DCDavid Cella
David Cella
TMTimothy G. G. Murray
Timothy G. G. Murray
CGCollaborative Ocular Melanoma Study-Quality Of Life Study Group
Collaborative Ocular Melanoma Study-Quality Of Life Study Group
Research from JAMA Ophthalmology — Development and Validation of Disease-Specific Measures for Choroidal Melanoma — COMS-QOLS Report No. 2

1 January 2013 in Ophthalmic Surgery, Lasers and Imaging Retina
Verified
Journal Article
Closed access
MLMarcela Lonngi
Marcela Lonngi
AGAaron S. Gold
Aaron S. Gold
TMTimothy G. G. Murray
Timothy G. G. Murray
Retinal astrocytic hamartoma or retinal astrocytoma is the best-known ocular manifestation of tuberous sclerosis complex, a neurocutaneous syndrome characterized by the development of multiple disseminated hamartomas. It can have several clinical presentations, ranging from unilateral transparent, noncalcified lesions to bilateral multinodular, mulberrylike calcified tumors. Symptoms appear if the tumor involves the macula and can cause visual loss on the basis of progressive retinal degeneration. The authors report a case of a patient with tuberous sclerosis, bilateral astrocytic hamartomas, and macular edema with intraretinal hemorrhage in the left eye that has responded well to treatment with bevacizumab and intravitreal triamcinolone acetonide.

1 October 2012 in Clinical Ophthalmology
Verified
Journal Article
Open access
TMTimothy G. G. Murray
Timothy G. G. Murray
HAHassan Aziz
Hassan Aziz
LSLa Senna
La Senna
MVMichael M. Vigoda
Michael M. Vigoda
CFCristina Fernandes
Cristina Fernandes
ASAziz- Sultan
Aziz- Sultan
Peer reviewed article authored by (Aziz HA, LaSenna CE, Vigoda M, Fernandes C, Feuer W, Aziz-Sultan MA, Murray TG). Read article or submit your manuscript for publishing.